UniProt functional annotation for P55222



	UniProt functional annotation for P55222

UniProt code: P55222.

Organism: Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1).

Taxonomy: Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales; Pseudomonadaceae; Pseudomonas.

Function: Global cAMP-dependent transcriptional regulator that controls virulence gene expression by distinct cAMP-dependent and -independent mechanisms, which allow to fine tune its virulence program in response to specific host cues or environments (PubMed:20494996). Controls the expression of many regulatory targets including type II, type III and type IV secretion systems, flagellar-mediated motility, and quorum sensing systems (PubMed:9190808, PubMed:12057955, PubMed:26929300, PubMed:30761117). Transcriptional control is exerted by binding to a well-characterized consensus site (5'-ANWWTGNGAWNYAGWTCACAT) within target promoters (PubMed:17159200, PubMed:20494996, PubMed:26929300). Directly binds to the toxA upstream region to regulate exotoxin A production, to the lasR gene promoter to activate the las quorum- sensing system or to the exsA promoter to regulate type III secretion system (PubMed:9190808, PubMed:12057955, PubMed:19389782). Autoregulates as well its own expression (PubMed:20494996). {ECO:0000269|PubMed:12057955, ECO:0000269|PubMed:17159200, ECO:0000269|PubMed:19389782, ECO:0000269|PubMed:20494996, ECO:0000269|PubMed:26929300, ECO:0000269|PubMed:30761117, ECO:0000269|PubMed:9190808}.

Subunit: Homodimer. {ECO:0000269|PubMed:21665969}.

Induction: Regulated by both cAMP and cGMP to allow differential regulation of different regulons (PubMed:12057955). Cyclic AMP is required for Vfr binding to vfr, regA, ptxR, and cpdA promoter DNA (PubMed:20494996, PubMed:25897033). Cyclic GMP instead inhibits the formation of Vfr-DNA complexes (PubMed:20494996, PubMed:25897033). {ECO:0000269|PubMed:12057955, ECO:0000269|PubMed:20494996, ECO:0000269|PubMed:25897033}.

Disruption phenotype: Mutants show loss of twitching motility and are defective in type IV pilus assembly (PubMed:12057955). Expression of ExsA is also strongly affected in the mutant (PubMed:26929300). {ECO:0000269|PubMed:12057955, ECO:0000269|PubMed:26929300}.

Annotations taken from UniProtKB at the EBI.


Organism:		Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1).
Taxonomy:		Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales; Pseudomonadaceae; Pseudomonas.



Function:		Global cAMP-dependent transcriptional regulator that controls virulence gene expression by distinct cAMP-dependent and -independent mechanisms, which allow to fine tune its virulence program in response to specific host cues or environments (PubMed:20494996). Controls the expression of many regulatory targets including type II, type III and type IV secretion systems, flagellar-mediated motility, and quorum sensing systems (PubMed:9190808, PubMed:12057955, PubMed:26929300, PubMed:30761117). Transcriptional control is exerted by binding to a well-characterized consensus site (5'-ANWWTGNGAWNYAGWTCACAT) within target promoters (PubMed:17159200, PubMed:20494996, PubMed:26929300). Directly binds to the toxA upstream region to regulate exotoxin A production, to the lasR gene promoter to activate the las quorum- sensing system or to the exsA promoter to regulate type III secretion system (PubMed:9190808, PubMed:12057955, PubMed:19389782). Autoregulates as well its own expression (PubMed:20494996). {ECO:0000269\|PubMed:12057955, ECO:0000269\|PubMed:17159200, ECO:0000269\|PubMed:19389782, ECO:0000269\|PubMed:20494996, ECO:0000269\|PubMed:26929300, ECO:0000269\|PubMed:30761117, ECO:0000269\|PubMed:9190808}.


Subunit:		Homodimer. {ECO:0000269\|PubMed:21665969}.
Induction:		Regulated by both cAMP and cGMP to allow differential regulation of different regulons (PubMed:12057955). Cyclic AMP is required for Vfr binding to vfr, regA, ptxR, and cpdA promoter DNA (PubMed:20494996, PubMed:25897033). Cyclic GMP instead inhibits the formation of Vfr-DNA complexes (PubMed:20494996, PubMed:25897033). {ECO:0000269\|PubMed:12057955, ECO:0000269\|PubMed:20494996, ECO:0000269\|PubMed:25897033}.
Disruption phenotype:		Mutants show loss of twitching motility and are defective in type IV pilus assembly (PubMed:12057955). Expression of ExsA is also strongly affected in the mutant (PubMed:26929300). {ECO:0000269\|PubMed:12057955, ECO:0000269\|PubMed:26929300}.